Probiotics in cystic fibrosis patients: A double blind crossover placebo controlled study

Biervliet, S. Van; Hauser, Bruno; Verhulst, Stijn; Stepman, Hedwig; Delanghe, Joris; Warzee, Jean-Pol; Pot, Bruno; Vandewiele, Tom; Wilschanski, Michael

doi:10.1016/j.clnesp.2018.06.008

Cited by 31 publications

(26 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Probiotic treatment is defined here as the administration of live microbes with putative health benefits. The most consistent finding from probiotic clinical trials in pwCF is a reduction in respiratory exacerbations ( 57 , 163 , 164 ), although this result is not consistent across all studies ( 165 ). Notably, probiotic treatments can be formulated with one or more microbial strains, and probiotic composition varies between CF clinical trials.…”

Section: Remediating the Cf Microbiotamentioning

confidence: 99%

See 1 more Smart Citation

The Gut-Lung Axis in Cystic Fibrosis

Price

O’Toole

2021

J Bacteriol

View full text Add to dashboard Cite

Cystic Fibrosis (CF) is a heritable, multi-organ disease that impacts all tissues that normally express CFTR protein. While importance of the airway microbiota has long been recognized, the intestinal microbiota has only recently been recognized as an important player in both intestinal and lung health outcomes for persons with CF (pwCF). Here, we summarize current literature related to the gut-lung axis in CF, with a particular focus on three key ideas: Mechanisms through which microbes influence the gut-lung axis, drivers of microbiota alterations, and the potential for intestinal microbiota remediation.

show abstract

Section: Remediating the Cf Microbiotamentioning

confidence: 99%

“…Several of the probiotic clinical trials mentioned above use the crossover method, allowing individual patients to serve as their own controls ( 71 , 165 , 166 ). This approach can be powerful for studies of pwCF, where patient populations are small and interindividual variability is high.…”

Section: Remediating the Cf Microbiotamentioning

confidence: 99%

The Gut-Lung Axis in Cystic Fibrosis

Price

O’Toole

2021

J Bacteriol

View full text Add to dashboard Cite

show abstract

“…Lactobacillus administration caused a reduction in bacterial density and an increase in microbial diversity in the gut [68], as well as beneficial effects on exacerbation risk and quality of life in CF patients [69]. However, some inconsistent results were also yielded; for example, Van Biervliet et al found no significant differences in pulmonary function and disease exacerbations between probiotic and placebo groups [70]. Therefore, according to a meta-analysis, fastidiously designed and adequate RCTs are needed to assess the safety and efficacy of probiotics and to ascertain the specific probiotic strains or dose that can be of significant benefit for CF patients [71].…”

Section: The Gut Microbiota and Respiratory Diseasesmentioning

confidence: 99%

The Gut Microbiota and Respiratory Diseases: New Evidence

Liu

Yuan

et al. 2020

Journal of Immunology Research

151

View full text Add to dashboard Cite

Human body surfaces, such as the skin, intestines, and respiratory and urogenital tracts, are colonized by a large number of microorganisms, including bacteria, fungi, and viruses, with the gut being the most densely and extensively colonized organ. The microbiome plays an essential role in immune system development and tissue homeostasis. Gut microbiota dysbiosis not only modulates the immune responses of the gastrointestinal (GI) tract but also impacts the immunity of distal organs, such as the lung, further affecting lung health and respiratory diseases. Here, we review the recent evidence of the correlations and underlying mechanisms of the relationship between the gut microbiota and common respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), lung cancer, and respiratory infection, and probiotic development as a therapeutic intervention for these diseases.

show abstract

“…[66][67][68] Furthermore, as negative results are seldom published, it eventually leads to publication bias in literature analysis. In a recent double blind crossover placebo controlled study, Van Biervliet et al 69 could not validate the previously reported beneficial effects of probiotic supplementation since no significant associations were found for fecal calprotectin and pulmonary exacerbations; although a positive effect on gut permeability was noted. Additionally, Bruzzese et al 70 designed a multicentre RCT to evaluate the effect of Lactobacillus GG, supplemented for a period of 12 months, on pulmonary exacerbations and hospitalization in children aged 2-16 years The Lung Microbiome in Neonates of age with CF.…”

Section: Therapeutic Interventions Targeting the Lung Microbiomementioning

confidence: 84%

The lung microbiome in neonates

et al. 2019

View full text Add to dashboard Cite

Despite the advent of culture-independent techniques to identify members of the microbiome, studies focusing on the lung microbiome of neonates are scarce. Understanding the role of the microbiome in the pathogenesis of pulmonary conditions affecting newborns could lead to the initiation of pioneering therapeutic interventions, which could potentially prevent lifelong disability. Bronchopulmonary dysplasia (BPD) has been associated with a less diverse microbiome, presence of Ureaplasma species and reduced Lactobacillus detection. Additionally, the potential role of microbial dysbiosis in the pathogenesis of asthma, cystic fibrosis and pneumonia has been described. There has also been a surge of interest in attempting to elucidate the interactions between the airway and gut microbiomes and their bearings on respiratory health and diseases to eventually broaden the scope of therapeutic interventions.

show abstract

Probiotics in cystic fibrosis patients: A double blind crossover placebo controlled study

Cited by 31 publications

References 26 publications

The Gut-Lung Axis in Cystic Fibrosis

The Gut-Lung Axis in Cystic Fibrosis

The Gut Microbiota and Respiratory Diseases: New Evidence

The lung microbiome in neonates

Contact Info

Product

Resources

About